Education
About Us
Working with TipRanks
Follow Us
Nektar Therapeutics (NKTR)
NASDAQ:NKTR
NKTR Stock Chart & Stats
$62.57
-$0.04(-3.36%)
At close: 4:00 PM EST
$62.57
-$0.04(-3.36%)
Day’s Range― - ―
52-Week Range$6.49 - $65.79
Previous CloseN/A
Volume706.47K
Average Volume (3M)1.07M
Market Cap
$1.14B
Enterprise Value$364.84M
Total Cash (Recent Filing)$175.90M
Total Debt (Recent Filing)$96.16M
Price to Earnings (P/E)―
Beta3.89
Next Earnings
Nov 06, 2025EPS Estimate
-2.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.95
Shares Outstanding19,018,574
10 Day Avg. Volume1,053,839
30 Day Avg. Volume1,067,520
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue4.87
Enterprise Value/Gross Profit5.86
Enterprise Value/Ebitda-4.07
Forecast
1Y Price Target
$93.86Price Target Upside50.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Mechanism Of ActionRezpeg’s therapeutic potential is further solidified by its highly differentiated mechanism of action as a Treg agonist, distinct from currently approved treatments.
Patient BenefitsPatient-reported outcomes demonstrated significant benefits for rezpeg, including improvements in quality of life, disease control, sleep, and pain reduction.
Therapeutic PotentialRezpeg achieved statistical significance on the primary endpoint and all key secondary endpoints, indicating its strong therapeutic potential.
Bears Say
Differentiation ConcernsThe newly disclosed data does not materially alter the view on rezpeg as questions around its differentiation remain unanswered.
Market PositionRezpeg is not expected to displace Dupixent as the main front-line biologic in atopic dermatitis.
Treatment LandscapeAnalysts struggle with where rezpeg might fit in the treatment paradigm as the phase II REZOLUTE results do not support its use as a front-line biologic in AD.
Nektar Therapeutics News
NKTR FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Nektar Therapeutics lowest stock price was $6.49 and its highest was $65.79 in the past 12 months.
What is Nektar Therapeutics’s market cap?
Nektar Therapeutics’s market cap is $1.14B.
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 8 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on Aug 07, 2025. The company reported -$2.95 earnings per share for the quarter, beating the consensus estimate of -$3.028 by $0.078.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -2.69.
How many shares outstanding does Nektar Therapeutics have?
Nektar Therapeutics has 19,018,574 shares outstanding.
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -$2.95 in its last earnings report, beating expectations of -$3.028. Following the earnings report the stock price went up 6.023%.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Currently, no hedge funds are holding shares in NKTR
Nektar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$93.86 (50.01% Upside)
$93.86 (50.01% Upside)
Blogger Sentiment
Bullish
NKTR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 66.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $61.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 8.0%
Last 30 Days ▲ 8.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
216.01%
12-Months-Change
Fundamentals
Return on Equity
-440.80%
Trailing 12-Months
Asset Growth
-39.55%
Trailing 12-Months
Company Description
Nektar Therapeutics
Nektar Therapeutics (NKTR) is a biopharmaceutical company focused on discovering and developing innovative therapies to treat serious illnesses, particularly in the fields of oncology, immunology, and chronic pain. The company utilizes its proprietary drug development platform to create novel therapeutics that enhance the immune response to cancer and other diseases. Nektar's core products include NKTR-214, an immuno-oncology candidate designed to activate the body's immune response, and other candidates targeting various unmet medical needs.
NKTR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, with strong data for REZPEG in atopic dermatitis and a solid financial position enabling future clinical advancements. The company is actively preparing for Phase III trials and expanding its market potential. However, challenges such as net losses, injection site reactions, and ongoing litigation with Lilly were noted.View all NKTR earnings summariesNKTR Stock 12 Month Forecast
Average Price Target
$93.86
▲(50.01% Upside)
Technical Analysis
Wave Life Sciences
―
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
5.30% Insiders
8.48% Mutual Funds
0.03% Other Institutional Investors
79.58% Public Companies and Individual Investors